Table 2 Percentage change in cardiac markers from Baseline to visit 4
From: Timing of SGLT2i initiation after acute myocardial infarction
Treatment Initiation | |||||
|---|---|---|---|---|---|
< 24 h (N = 41) | 24–48 h (N = 193) | > 48– < 72 h (N = 229) | P-value | Pinteraction | |
Median (IQR) | Median (IQR) | Median (IQR) | |||
LVEF (%) | |||||
Empagliflozin | 7.0 (− 3.4; 13.7) | 3.6 (− 2.0; 9.1) | 0.00 (− 5.5; 9.1) | 0.239 | 0.550 |
Placebo | 1.7 (− 1.7; 12.5) | 2.2 (− 7.3; 10.6) | 3.4 (− 3.9; 12.1) | 0.898 | |
E/é | |||||
Empagliflozin | − 9.5 (− 11.3; 9.6) | − 4.9 (− 22.4; 8.9) | − 4.2 (− 18.6; 7.7) | 0.664 | 0.863 |
Placebo | − 5.6 (− 10.0; − 0.3) | 1.1 (− 11.5; 17.3) | − 1.1 (− 14.3; 13.5) | 0.720 | |
LVESD (mm) | |||||
Empagliflozin | − 2.9 (− 9.8; 6.1) | 2.6 (− 5.4; 13.5) | 0.00 (− 8.3; 9.7) | 0.225 | 0.088 |
Placebo | 1.3 (− 18.9; 7.5) | 3.0 (− 5.6; 8.8) | 0.00 (− 7.0; 9.5) | 0.763 | |
LVEDD (mm) | |||||
Empagliflozin | − 2.9 (− 10.3; 3.8) | 0 (− 6.3; 5.4) | 0.00 (− 4.9; 4.0) | 0.998 | 0.622 |
Placebo | − 1.8 (− 9.5; 1.8) | 1.7 (− 3.6; 4.7) | 0.00 (− 6.0; 4.9) | 0.158 | |